A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RISVODETINIB, A SELECTIVE C-ABL INHIBITOR, IN UNTREATED PARKINSON&#39;S DISEASE

risvodetinib (IkT-148009) - Inhibikase, Clintrex

Milton H. Werner; C W. Olanow; Andrew McGarry; Christopher Meyers; Emaryn Mancino; Carl Klint; Jacqueline Pellecchia

Mar 11, 2025